A carregar...
Low-dose HDACi potentiates anti-tumor activity of macrophages in immunotherapy
The success of checkpoint immunotherapy has created optimism that cancer may be curable. However, not all patients respond, resistance is common and many patients relapse owing to immune escape. We demonstrate that HDAC inhibition not only decreases the trafficking of myeloid-derived suppressor cell...
Na minha lista:
| Publicado no: | Oncoimmunology |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8183541/ https://ncbi.nlm.nih.gov/pubmed/34123577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1935668 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|